NCT00960479View on ClinicalTrials.gov

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

February 28, 2001

Study Completion Date

February 28, 2001

Conditions
Chronic Hepatitis C
Interventions
DRUG

Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)

DRUG

Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY